G1 Therapeutics Makes Key Appointments to Management Team
G1 Therapeutics, Inc. (GTHX)
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
g1therapeutics.com/pages/investors/investors.htm
Company Research
Source: GlobeNewswire
Terry Murdock appointed Senior Vice President, Development OperationsShannon Morris, MD, PhD, named Vice President, Clinical Development RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the appointments of Terry Murdock as Senior Vice President, Development Operations, and Shannon Morris, MD, PhD, as Vice President, Clinical Development. “I’m excited to welcome Terry and Shannon to G1, and am confident their proven leadership and broad experience will help us maximize the potential of our oncology pipeline,” said Mark Velleca, MD, PhD, Chief Executive Officer of G1 Therapeutics. “Terry’s impressive track record in global clinical development, specifically in oncology, makes him an excellent fit to guide G1 in clinical operations, drug manufacturing, and project management. Shannon brings a deep knowledge of oncology clinical practice as well as drug discovery and development expe
Show less
Read more
Impact Snapshot
Event Time:
GTHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GTHX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GTHX alerts
High impacting G1 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GTHX
News
- G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024GlobeNewswire
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.MarketBeat
- G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
GTHX
Earnings
- 2/28/24 - Beat
GTHX
Sec Filings
- 4/12/24 - Form PRE
- 4/9/24 - Form 144
- 3/22/24 - Form 8-K
- GTHX's page on the SEC website